Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02032004 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure
A Phase 3 study, sponsored by Mesoblast.
- Completed
- Registry status
- Phase 3
- Development phase
- 565
- Enrollment target
NCT02032004 is a Phase 3 study that has completed, run by Mesoblast. The registered enrollment target is 565 participants.
The verdict
NCT02032004, a Phase 3 study, has completed, sponsored by Mesoblast.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 565 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine whether transendocardial delivery of allogeneic human bone marrow-derived mesenchymal precursor cells (MPCs \[rexlemestrocel-L\]) is effective in the treatment of chronic heart failure (HF) due to left ventricular (LV) systolic dysfunction.
Interventions
- OTHER Sham Comparator
- BIOLOGICAL Rexlemestrocel-L
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 565 participants |
| Start Date | 2014-03-03 |
| Est. Completion | 2020-01-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02032004
The ClinicalTrials.gov registry entry for NCT02032004 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 565 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mesoblast, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sham Comparator is the first listed.
NCT02032004 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02032004 about?
NCT02032004 is a clinical study titled "Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure". The primary objective of this study is to determine whether transendocardial delivery of allogeneic human bone marrow-derived mesenchymal precursor cells (MPCs \[rexlemestrocel-L\]) is effective in the treatment of chronic heart failure (HF) due to left ventricular (LV) systolic dysfunction.
What is the current status of trial NCT02032004?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 565 participants. The study started on 2014-03-03. Estimated completion is 2020-01-30.
What interventions are being tested in trial NCT02032004?
The interventions under investigation include: Sham Comparator (OTHER), Rexlemestrocel-L (BIOLOGICAL).
Who is sponsoring clinical trial NCT02032004?
This trial is sponsored by Mesoblast, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.